Palbociclib 125mg Capsules

Palbociclib 125mg Capsules contain palbociclib 125mg, an oral prescription cyclin-dependent kinase 4/6 (CDK4/6) inhibitor used as targeted treatment for adults with hormone receptor-positive (HR-positive), HER2-negative advanced or metastatic breast cancer. It is used in combination with an aromatase inhibitor as initial endocrine-based therapy or with fulvestrant following progression after endocrine therapy.

Palbociclib works by inhibiting CDK4 and CDK6, proteins involved in cell-cycle progression. By interfering with these pathways, it can slow the proliferation of susceptible breast cancer cells. The 125mg capsule is the established starting strength, with treatment generally administered once daily for 21 consecutive days followed by 7 days off, forming a 28-day cycle.

Ibrance® is the reference brand containing palbociclib. Palbociclib 125mg Capsules are prescription oncology medicines and should be used under the supervision of a qualified oncologist.

Product Information

Generic Name

Palbociclib

Active Ingredient

Palbociclib

Strength

125mg

Dosage Form

Capsule

Drug Class

Cyclin-Dependent Kinase 4/6 (CDK4/6) Inhibitor

Therapeutic Class

Targeted Anticancer Therapy

Reference Brand

Ibrance®

Manufacturer of Reference Brand

Pfizer

Route

Oral

Primary Indication

HR-positive, HER2-negative advanced or metastatic breast cancer

Combination Therapy

Aromatase inhibitor or fulvestrant, depending on treatment setting

Prescription

Yes

Starting Strength

125mg

Typical Schedule

21 consecutive days of treatment followed by 7 days off

Administration

Oral, with food for the capsule formulation

Pack Size

Manufacturer/market dependent

What Is Palbociclib 125mg?

Palbociclib is an oral targeted anticancer medicine belonging to the CDK4/6 inhibitor class.

CDK4 and CDK6 are enzymes involved in controlling the progression of cells through the cell cycle. In certain breast cancers, increased activity of these pathways contributes to continued cancer-cell proliferation.

Palbociclib inhibits CDK4 and CDK6, helping interfere with cell-cycle progression and limiting the multiplication of susceptible cancer cells. This targeted mechanism distinguishes palbociclib from traditional cytotoxic chemotherapy.

Palbociclib 125mg for Breast Cancer

Palbociclib has an established role in the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer.

It is generally administered together with endocrine therapy rather than used as conventional chemotherapy. Depending on the treatment setting, the endocrine partner may be an aromatase inhibitor or fulvestrant.

The principal treatment relationship is:

Palbociclib 125mg → Palbociclib Capsules → Generic Ibrance 125mg → CDK4/6 Inhibitor → HR-Positive HER2-Negative Breast Cancer → Targeted Breast Cancer Treatment

Palbociclib 125mg and Ibrance®

Ibrance® contains palbociclib and is the established reference brand marketed by Pfizer. Pfizer's current product information lists Ibrance in 75mg, 100mg and 125mg capsule strengths.

Palbociclib 125mg is therefore commonly searched alongside terms such as Ibrance 125mg, Generic Ibrance 125mg, Palbociclib 125mg Generic, Palbociclib 125mg Capsules and Ibrance 125mg Alternative.

Palbociclib 125mg Monitoring

Treatment with palbociclib generally requires regular medical monitoring, including:

• Complete blood count
• Neutrophil count
• Hemoglobin
• Platelet count
• Liver function where clinically appropriate
• Signs of infection
• Treatment response
• Adverse reactions and tolerability

The prescribing information recommends complete blood-count monitoring before treatment and at specified points during treatment, particularly during the initial cycles.

Palbociclib also has clinically important drug interactions. Grapefruit products and strong CYP3A inhibitors or inducers may affect palbociclib exposure and should be discussed with the treating healthcare professional.

Palbociclib 125mg and Endocrine Therapy

Palbociclib is commonly combined with endocrine therapy for HR-positive breast cancer.

Depending on the indication, treatment can include:

• Aromatase inhibitors
• Fulvestrant

The appropriate combination is selected according to the patient's cancer characteristics, previous treatment and clinical circumstances.

Availability & Ordering

Palbociclib 125mg Capsules are prescription oncology medicines supplied for eligible patients under medical supervision.

Customers searching for Palbociclib 125mg Capsules, Palbociclib 125mg, Generic Palbociclib 125mg, Generic Ibrance 125mg, Ibrance 125mg, Buy Palbociclib 125mg, Buy Palbociclib Online, Palbociclib 125mg Price, Palbociclib Supplier, Palbociclib 125mg Online, Ibrance Alternative and related commercial terms can find the product through appropriately licensed pharmacies or authorized pharmaceutical suppliers.

Availability, prescription requirements, import regulations and dispensing requirements vary across the USA, UK, UAE/Dubai, Australia, Singapore, Thailand, China and Russia.

How it works

Palbociclib selectively inhibits cyclin-dependent kinases 4 and 6.

CDK4/6 activity helps regulate progression through the cell cycle. Blocking these enzymes can prevent susceptible cancer cells from progressing normally through the cell cycle, thereby reducing cancer-cell proliferation.

This makes palbociclib a targeted cell-cycle therapy used particularly in hormone receptor-positive breast cancer.

Palbociclib is primarily used for adults with HR-positive, HER2-negative advanced or metastatic breast cancer.

Approved treatment combinations include:

• Palbociclib with an aromatase inhibitor as initial endocrine-based therapy
• Palbociclib with fulvestrant following disease progression after endocrine therapy

The appropriate endocrine partner depends on the patient's treatment history, menopausal status, disease characteristics and prescribing information applicable to the country.

The recommended starting dose for the capsule formulation is 125mg once daily for 21 consecutive days followed by 7 days off treatment, completing a 28-day cycle. Ibrance capsules should be taken with food and swallowed whole.

Dose interruptions or reductions may be necessary depending on blood counts, adverse reactions, drug interactions and individual tolerability.

Patients should follow the dosage and schedule prescribed by their oncologist and should not independently change or discontinue treatment.

Palbociclib can cause adverse reactions and requires medical monitoring.

Common adverse effects include:

• Neutropenia
• Leukopenia
• Infections
• Fatigue
• Nausea
• Anemia
• Thrombocytopenia
• Diarrhea
• Decreased appetite
• Stomatitis
• Hair loss

Neutropenia is one of the most clinically important adverse effects associated with palbociclib. Regular blood-count monitoring is therefore an important part of treatment.

Rare but serious interstitial lung disease/pneumonitis has also been reported. New or worsening respiratory symptoms should be reported promptly to a healthcare professional.